RAPT Therapeutics sets USD 58 merger: what it means for RAPT Therapeutics stock
Published on 10/02/2026 at 17:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
RAPT Therapeutics set a USD 58.00 cash settlement as its corporate transaction moved the clinical-stage biotechnology company out of public trading. IT Boltwise reported on October 1, 2026, that a corporate-actions entry dated September 22, 2026, specified the fixed consideration. The transaction gives the former RAPT Therapeutics stock a clearly defined cash outcome rather than a continuing public-market story.
The USD 58 settlement
The settlement figure is the central number for shareholders: USD 58.00 per share. StockTitan reported from GSK's September 2026 Form 6-K that GSK completed the acquisition on March 3, 2026, paying USD 58.00 per share and an aggregate USD 2.3 billion including transaction fees.
The filing also gives the transaction a strategic dimension. GSK acquired 100 percent of RAPT Therapeutics and the rights to ozureprubart, while excluding mainland China, Macau, Taiwan and Hong Kong from the global rights package.
Ozureprubart becomes the asset
RAPT's most important asset is ozureprubart, a long-acting anti-immunoglobulin E antibody designed for prophylactic protection against food allergens. The program was in phase IIb development in 2026, a stage that places clinical readouts and regulatory progress ahead of commercial revenue in the investment narrative.
The company describes ozureprubart as a treatment designed around dosing every 12 weeks. RAPT Therapeutics identified the program as a leading focus of its work on inflammatory and immunologic diseases in its January 20, 2026 company update.
What the deal means for stock
For RAPT Therapeutics stock, the USD 58.00 per-share settlement and USD 2.3 billion aggregate value define the transaction outcome. The operating story now sits inside GSK's pipeline, where ozureprubart's phase IIb progress and the potential 12-week dosing schedule are the measurable milestones that carry the former company's scientific value forward.
RAPT Therapeutics at a glance
- Company: RAPT Therapeutics, Inc.
- Ticker: RAPT
- Sector / Industry: Healthcare / Biotechnology
- Transaction consideration: USD 58.00 per share
- Aggregate transaction value: USD 2.3 billion including transaction fees
- Key asset: Ozureprubart, phase IIb anti-immunoglobulin E program
